GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2024
0mins
Source: SeekingAlpha
- Gainers: Clever Leaves Holdings (CLVR) +10%, Nutriband (NTRB) +13%, GoodRx Holdings (GDRX) +10%, Celcuity (CELC) +9%, INVO Bioscience (INVO) +10%
- Losers: 180 Life Sciences (ATNF) -24%, Omeros Corporation (OMER) -22%, Eyenovia (EYEN) -22%, Inhibikase Therapeutics (IKT) -15%, Seelos Therapeutics (SEEL) -10%
- S&P 500 Health Care Sector: -0.29% to 1697.09
- Health Care Equipment & Services: +0.17% to 1964.83
- Pharmaceuticals, Biotechnology & Life Science: -0.63% to 1392.52
Analyst Views on OMER
Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 43.67 USD with a low forecast of 36.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.150
Low
36.00
Averages
43.67
High
55.00
Current: 12.150
Low
36.00
Averages
43.67
High
55.00
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
